These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31161433)

  • 1. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.
    Yamada Y; Fujii H; Ohata K; Kato-Hayashi H; Watanabe D; Ishihara T; Uemura S; Iwashita T; Imai H; Matsuhashi N; Takahashi T; Sugiyama T; Shimizu M; Yoshida K; Suzuki A
    Med Oncol; 2019 Jun; 36(7):63. PubMed ID: 31161433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer.
    Mao C; He Y; Xu N; Yan H; Zhang N; Cheng G; Jiang H; Chen M; Chen Y; Wang X; Gu Y; Shen P; Zhang G; Yan J; Yang Z; Ding L; Han Z; Wang Z; Zhang J; Zheng W; Wang J; Qin S
    Immun Inflamm Dis; 2024 Aug; 12(8):e1348. PubMed ID: 39105572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
    Irisawa A; Takeno M; Watanabe K; Takahashi H; Mitsunaga S; Ikeda M
    Sci Rep; 2022 Sep; 12(1):15574. PubMed ID: 36114233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
    Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
    Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
    Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
    Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
    Tong H; Fan Z; Liu B; Lu T
    Sci Rep; 2018 Jun; 8(1):8666. PubMed ID: 29875415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06.
    Morinaga S; Takita M; Yoshizawa A; Kamei K; Nakamori S; Ishihara S; Kuramochi H; Yokoyama Y; Uchiyama T; Murohisa G; Ishigaki M; Todaka A; Fukutomi A
    Pancreas; 2020; 49(10):1372-1377. PubMed ID: 33122527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
    Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
    Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
    Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
    Keum J; Lee HS; Kang H; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):651-659. PubMed ID: 32185483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
    Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
    Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
    Kanesada K; Tsunedomi R; Hazama S; Ogihara H; Hamamoto Y; Shindo Y; Matsui H; Tokumitsu Y; Yoshida S; Iida M; Suzuki N; Takeda S; Ioka T; Nagano H
    Cancer Med; 2023 Feb; 12(4):4294-4305. PubMed ID: 36308049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 20. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.